Skip to main navigation menu Skip to main content Skip to site footer

Research Article

Vol. 8 No. 2 (2005)

Comparative DNA Flow Cytometric Study of Primary Intraocular and Central Nervous System Lymphomas

  • Teresa Martinu, MDCM
  • Claudia P. Correia, MD
  • Andersson M. Figueiredo, MD
  • Miguel N. Burnier Jr., MD, PhD
November 8, 2020


Primary intraocular lymphoma is generally considered as a subset of primary CNS lymphoma. This study attempts to show that they may in fact represent distinct entities by comparing their respective proliferation rates using DNA flow cytometry. Four samples of primary intraocular lymphoma and seven samples of primary CNS lymphoma were analyzed, all from paraffin-embedded tissue. All tumors were of the large B-cell type. A normal human tonsil sample was used as a control. Tissue samples were analyzed by DNA flow cytometry, which is a precise and objective method to measure DNA content and cell proliferation of a tumor. S-phase fraction (SPF) and DNA content were measured for each sample. The average SPF for primary intraocular lymphoma was significantly higher than that of primary CNS lymphoma, 23.8 (range: 18.9 to 29.6) versus 15.1 (range: 1.1 to 25.1) respectively. Of the 11 tumors analyzed, 2 brain tumors were aneuploid and 1 eye tumor was peridiploid. All other tumors were diploid. Thus, no significant pattern was detected in the DNA content of the tumors. This lack of clinical significance of tumor aneuploidy is consistent with data reported in the literature. The results of this study indicate that primary intraocular lymphoma is more aggressive and of higher grade than primary CNS lymphoma. The different proliferation rates of intraocular and CNS lymphomas may be explained by either their different spatial location or a distinct genetic composition, the latter reinforcing the hypothesis that the two are fundamentally different entities


  1. Grant JW, Isaacson PG. Primary Central Nervous System Lymphoma. Brain Pathology 1992;2:97-109.
  2. Char DH, Ljung BM, Miller T, Phillips T. Primary Intraocular Lymphoma (ocular reticulum cell sarcoma) Diagnosis and Management. Ophthalmology 1988;95:625-630.
  3. Hen-linger U. Primary CNS lymphoma: Findings outside the brain. Journal of Neuro-Oncology 1999;43:227-230.
  4. Deangelis LM. Current Management of Primary Central Nervous System Lymphoma. Oncology 1995; 9:63-71.
  5. Bataille B, Delwail V, Menet E, et al. Primary Intracerebral Malignant Lymphoma: Report of 248 cases. Journal of Neurosurgery 2000;92:261-266.
  6. Carvalho AM, Martinu T, Figueiredo AP, Correia CP, Bumier MNJr. Invest Ophthalmol Vis Sci 41 (Suppi): 4, 2000
  7. Peterson K, Gordon KB, Heineman MH, DeAngelis LM. The Clinical Spectrum of Ocular Lymphoma. Cancer 1993;72:843-849.
  8. Freeman LN, Schachat AP, Knox DL, et al. Clinical Features, Laboratory Investigations, and Survival in Ocular Reticulum Cell Sarcoma. Ophthalmology 1987;94:16311639.
  9. Wilson DJ, Braziel R, Rosenbaum JT. Intraocular Lymphoma: Immunopathologic Analysis of Vitreous Biopsy Specimens. Arch Ophthalmol 1992;! 10:1455-1458.
  10. Ljung BM, Char D, Miller TR, Deschenes J. Intraocular Lymphoma: Cytologic Diagnosis and the Role of Immunologic Markers. The International Academy of Cytology Acta Cytologica 1988;32840-847.
  11. Lopez JS, Chan CC, Bumier M, et al. Immunohistochemistry Findings in Primary Intraocular Lymphoma. American Journal of Ophthalmology 1991;12:472-474.
  12. McLean IW, Bumier MN, Zimmerman LE, Jakobiec FA. Atlas of Tumor Pathology: Tumors of the Eye and Ocular Adnexa. Washington DC: Armed Forces Institute of Pathology, 1993;138-141.
  13. Bumier MN, Blanco G. Masquerade Syndrome: Primary Intraocular Lymphoma. In YannofM. Ophthalmology 1998:241-244.
  14. Akpek EK, Ahmed I, Hochberg FH, et al. Intraocular-Central Nervous System Lymphoma: Clinical Features, Diagnosis, and Outcomes. Ophthalmology 1999;106:1805-1810.
  15. Whitcup SM, de Smet MD, Rubin BI, et al. Intraocular Lymphoma. Ophthalmology 1993;100:1399-1406.
  16. Paulus W. Classification, Pathogenesis and Molecular Pathology of Primary CNS Lymphomas. Journal ofNeuro-Oncology 1999,43:203-208.
  17. Brown MT, Me Clendon RE, Gockerman JP. Primary Central Nervous System Lymphoma with Systemic Metastasis: Case Report and Review. Journal of Neuro-Oncology 1995,23:207-221.
  18. Paulus W, Jellinger K. Comparison of integrin adhesion molecules expressed by primary brain lymphomas and nodal lymphomas. Acta Neuropathol 1993;86:360-364.
  19. O'Neill BP, Dinapoli RP, Kurtin PJ, Hebemiaim TM. Occult systemic Non-Hodgkin's Lymphoma (NHL) in patients initially diagnosed as Primary Central Nervous System Lymphoma (PCNSL): How much staging is enough? journal ofNeuroOncology 1995;25:67-71.
  20. Riley RS, Mahin EJ, Ross W. DNA Ploidy and Cell Cycle Analysis. In: Riley RS, Mahin EJ, Ross W, eds. Clinical Applications of Flow Cytometry. New-York: Igaku-Shoin, 1993;sect.II,chap.6.
  21. Riley RS. Clinical Applications of DNA Ploidy and Cell Cycle Analysis. In: Riley RS, Mahin EJ, Ross W, eds. Clinical Applications of Flow Cytometry. New-York: Igaku-Shoin, 1993;sect.II,chap.8.
  22. Rehn S, Glimelius B, Sundstrom C. A comparative Study of Proliferation-Associated Parameters in B-cell Non-Hodgkin Lymphoma. Hematological Oncology 1991;9:287-298.
  23. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
  24. Smaaland R, Lote K, Sothem RB, Laerum OD. DNA Synthesis and ploidy in Non-Hodgkin's Lymphomas Demonstrate Intrapatient Variation Depending on Circadian Stage of Cell Sampling. Cancer Research 1993,53:3129-3138.


Download data is not yet available.